IFF Gains Regulatory Approval For Use Of 2′-Fucosyllactose Human Milk Oligosaccharide (2'-FL HMO) In China
Portfolio Pulse from Benzinga Newsdesk
IFF has received regulatory approval from China for the use of 2′-Fucosyllactose Human Milk Oligosaccharide (2'-FL HMO). This approval could potentially open up a new market for IFF's product.
October 10, 2023 | 6:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IFF's approval for 2'-FL HMO in China could potentially increase its market share and revenues in the region.
Regulatory approval in a large market like China can significantly impact a company's revenues and market share. Given the size of the Chinese market, this approval could potentially lead to increased sales and revenues for IFF.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100